Orexin B
Aeterna does not sell peptides. External link, vendor independently verified.
Mechanism
Orexin B is a 28-amino-acid neuropeptide cleaved from the prepro-orexin precursor alongside its sibling, Orexin A. Where Orexin A carries a pyroglutamyl N-terminus and an intrachain disulfide bridge, Orexin B is linear – structurally simpler, yet no less consequential. Its signaling is weighted toward the OX2 receptor, a preference that shapes its distinct pharmacological character. The lateral hypothalamic neurons that synthesize both orexins project with unusual breadth: locus coeruleus, dorsal raphe, tuberomammillary nucleus, basal forebrain, spinal cord. This architecture is not incidental. It reflects a peptide whose biological role is less about a single function and more about the coherent integration of vigilance, metabolism, and autonomic state.
OX2 selectivity defines orexin B’s pharmacology more than broad receptor balance. Relative to orexin A, it binds preferentially to the OX2 receptor and therefore serves as a cleaner probe of arousal circuitry linked to sleep to wake transitions.
Arousal signaling is its principal functional domain. In experimental systems, OX2 activation promotes wakefulness and stabilizes vigilance states, though the effect is typically shorter-lived than that produced by orexin A.
Translational interest has centered on central nervous system delivery rather than peripheral use. Intranasal orexin B has been explored in rodent models of narcolepsy, but its short half-life and lower receptor affinity have limited therapeutic momentum relative to engineered orexin agonists.
Research utility lies in pathway separation. Orexin B is most often used as a comparative ligand to distinguish OX2-weighted effects from the broader signaling profile produced by orexin A.
What we observe
Measured changes in arousal
The outcomes below reflect patterns observed in peer-reviewed preclinical studies and, where available, early human translational work. Aeterna does not prescribe, dispense, or sell. No outcome listed here constitutes a clinical claim or a guarantee of individual effect. The literature is cited; the interpretation is yours.
01
Wakefulness Promotion
02
Cataplexy Like Attenuation
03
Feeding Modulation
04
Sympathetic Activation
05
Cognitive Vigilance
06
Metabolic Tone
Evidence
Research on Orexin B
The studies below are representative, not exhaustive. The literature on orexin neuropeptides spans more than two decades and several thousand publications. What follows is a considered selection – chosen for methodological clarity and relevance to the outcomes described above. Aeterna presents the literature; it does not interpret findings as clinical guidance.
Orexin B-induced wakefulness and suppression of sleep states: receptor selectivity and dose-response characterization in freely moving rats
Freely moving Sprague-Dawley rats receiving graded ICV doses of Orexin B showed dose-dependent increases in wakefulness duration and corresponding reductions in NREM sleep. Co-administration of a selective OX2R antagonist abolished the effect; OX1R blockade alone produced only partial attenuation, confirming OX2R as the primary arousal-mediating receptor for this peptide. EEG spectral analysis revealed increased high-frequency power during Orexin B-induced wakefulness, consistent with activated cortical states rather than quiet waking.
Differential roles of orexin receptor subtypes in feeding and arousal: evidence from selective agonist and knockout studies
Using OX1R- and OX2R-selective knockout lines alongside synthetic peptide infusions, investigators demonstrated that Orexin B’s orexigenic effect in the paraventricular nucleus is primarily OX2R-mediated, while its modest contribution to reward-associated feeding involves residual OX1R engagement. Orexin B increased 2-hour food intake in satiated wild-type animals but not in OX2R-null mice, providing genetic confirmation of receptor attribution. The study also noted that Orexin A produced a larger and more sustained feeding response, consistent with its higher OX1R affinity.
Translational prospects for orexin receptor agonism: lessons from native peptide pharmacology and implications for narcolepsy type 1
A systematic review of 47 preclinical studies examining native orexin peptide administration concluded that Orexin B’s OX2R selectivity profile makes it a more tractable pharmacological template for narcolepsy type 1 therapeutics than Orexin A, whose dual-receptor engagement complicates side-effect prediction. The review identified intranasal delivery as the most promising translational route, citing three proof-of-concept studies in non-human primates demonstrating detectable CSF peptide levels following intranasal administration. Authors noted that no human efficacy data for native Orexin B existed at time of publication and called for IND-stage trials.
From lyophilized powder to a usable solution.
Peptide
100 µg (lyophilized)
Diluent
Sterile 0.9% saline or sterile water for injection; some protocols add 0.1% bovine serum albumin to reduce adsorption to vessel walls
Final concentration
1 µg/µL (100 µL total volume) for stock; further dilution to 0.1–0.5 µg/µL for working solutions in ICV or intranasal protocols
01
Prepare the vial
02
Draw the diluent
03
Add slowly
04
Prepare the vial
Note
Dosing rythm
A patient titration
The dosing parameters below are drawn from published preclinical research and do not constitute a clinical protocol. Orexin B has no approved human dosing regimen. Aeterna does not prescribe. The phases below describe the dose ranges used in rodent and non-human primate research, presented here for educational orientation only.
Storage, caution, contradiction
Storage
Cold, dark, undisturbed
- Store lyophilized peptide at −20°C, protected from light and moisture; do not store in frost-free freezers subject to temperature cycling.
- Reconstituted solutions are stable for up to 7 days at 4°C when prepared in sterile saline with 0.1% BSA; discard if any turbidity or particulate matter is observed.
- For long-term storage of reconstituted stock, aliquot into single-use volumes and store at −80°C; avoid repeated freeze-thaw cycles, which accelerate peptide degradation.
- Do not expose to temperatures above 25°C for extended periods; peptide bond integrity is compromised by prolonged ambient heat, particularly in aqueous solution.
- Label all vials with preparation date, concentration, and diluent; Orexin B and Orexin A vials are visually indistinguishable and must be clearly differentiated in any research setting.
Side effects
What members describe
- Cardiovascular activation - elevated heart rate and transient blood pressure increases have been observed in rodent models following ICV administration; autonomic monitoring is standard in preclinical protocols.
- Hyperthermia - modest increases in core body temperature have been reported at higher ICV doses in rodents, consistent with sympathetic activation and brown adipose thermogenesis.
- Increased locomotor activity - arousal-promoting doses reliably increase spontaneous locomotion in rodents, which may confound behavioral endpoints not designed to account for activity level.
- Appetite dysregulation - orexigenic effects at hypothalamic injection sites may complicate metabolic studies; food access should be controlled in experimental designs examining non-feeding endpoints.
- Anxiety-like behavior - high-dose OX1R engagement, even partial, has been associated with increased anxiety-like responses in elevated plus-maze paradigms; effect is more pronounced with Orexin A but not absent with Orexin B.
Contradictions
Reasons to abstain
- Not for use in any human subject outside of an approved IND or equivalent regulatory framework; no human safety data for native Orexin B administration exist as of 2025.
- Contraindicated in research models with pre-existing cardiovascular instability; sympathomimetic effects may exacerbate arrhythmia or hypertensive states.
- Not appropriate for use alongside other CNS stimulants or sympathomimetic agents in preclinical protocols without explicit pharmacokinetic interaction data.
- Avoid in animal models with compromised blood-brain barrier integrity unless CNS penetration is the explicit study endpoint; peripheral effects may dominate and confound interpretation.
- Research use only. Aeterna does not prescribe, dispense, or sell this compound. Any application outside a registered research context falls outside the scope of this monograph.
Synergies
Orexin B combos to know
The combinations below reflect pairings reported or theorized in the preclinical literature, not clinical protocols. Peptide combinations introduce pharmacodynamic complexity that the literature has only partially characterized. Aeterna does not prescribe or dispense. These pairings are presented as intellectual context, not as recommendations.
FAQ
Your questions, patiently answered
The primary distinction is receptor selectivity. Orexin A binds OX1R and OX2R with roughly equal affinity; Orexin B binds OX2R with approximately tenfold greater affinity than OX1R. Structurally, Orexin A carries a pyroglutamyl N-terminus and an intrachain disulfide bridge that Orexin B lacks – making Orexin B linear and, in some respects, more tractable as a synthetic research tool. The functional consequence is that Orexin B’s arousal effects are more cleanly OX2R-mediated, while Orexin A engages a broader receptor landscape including the OX1R-rich circuits of the locus coeruleus and prefrontal cortex.
Orexin B, like most neuropeptides, is rapidly degraded by circulating peptidases – neprilysin and angiotensin-converting enzyme among them. The 4–6 minute plasma half-life reflects this vulnerability. In the CNS, where peptidase activity is lower, the effective duration of action is longer, which is why ICV administration has been the dominant preclinical route. The short peripheral half-life is precisely why intranasal delivery – which bypasses systemic circulation and deposits peptide directly onto olfactory and trigeminal nerve endings – has attracted translational interest.
Narcolepsy type 1 is characterized by the near-total loss of orexin-producing neurons in the lateral hypothalamus, resulting in deficiency of both Orexin A and Orexin B. The therapeutic logic of orexin replacement is straightforward; the pharmacological challenge is delivery. Because OX2R is the receptor most directly linked to the histaminergic arousal circuits whose failure produces excessive daytime sleepiness, Orexin B’s OX2R selectivity makes it a pharmacologically coherent candidate. No approved orexin peptide replacement therapy exists as of 2025, though small-molecule OX2R agonists are in clinical development.
Orexin B is a 28-amino-acid peptide with a molecular weight of approximately 2,937 Da – well above the threshold for passive CNS penetration. It does not cross the blood-brain barrier in meaningful quantities following peripheral administration. The field has pursued three strategies: ICV administration (effective but invasive, limited to preclinical use), intranasal delivery (non-invasive, exploits olfactory and trigeminal pathways, demonstrated in non-human primates), and small-molecule OX2R agonists that mimic the peptide’s receptor engagement without its delivery constraints. The intranasal route remains the most promising path for native peptide translational work.
The lateral hypothalamic orexin system is not solely a sleep-wake switch. Orexin neurons receive input from glucose-sensing cells and are inhibited by leptin – placing them within the broader architecture of energy homeostasis. Orexin B’s orexigenic effects, its activation of sympathetic thermogenic circuits, and its modulation of autonomic tone collectively suggest a peptide that integrates arousal state with metabolic demand. Whether this integration has therapeutic implications for metabolic disease independent of sleep disorders is an open question; the literature is suggestive but not yet definitive.
Aeterna does not prescribe, dispense, or sell Orexin B or any other compound. This monograph is an educational document – a translation of the published literature into a considered, accessible format. Sourcing decisions for research purposes rest entirely with the reader and must comply with all applicable institutional and regulatory frameworks.
In the same family
Further reading in the curriculum - adjacent peptides in the Aeterna library.
Sourcing · Independently verified
When you're ready, source thoughtfully.